Corvus Pharmaceuticals, Inc. (CRVS) Net Income (Loss) Attributable to Parent USD 2015 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Corvus Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to 2024.
  • Corvus Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$5.7 M, a 27.6% increase year-over-year.
  • Corvus Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$24.9 M, a 39.2% increase year-over-year.
  • Corvus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$27 M, a 34.6% increase from 2022.
  • Corvus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$41.3 M, a 4.47% increase from 2021.
  • Corvus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$43.2 M, a 621% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$24.9 M -$5.7 M +$2.17 M +27.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$27 M -$6.65 M +$3.16 M +32.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 -$30.2 M -$6 M +$8.83 M +59.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$39 M -$6.5 M +$1.86 M +22.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-07
Q1 2023 -$40.9 M -$7.87 M +$424 K +5.11% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$41.3 M -$9.82 M -$580 K -6.28% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 -$40.7 M -$14.8 M -$4.16 M -39% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$36.6 M -$8.36 M +$3.39 M +28.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$40 M -$8.3 M +$3.28 M +28.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$43.2 M -$9.24 M -$36.6 M -134% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-19
Q3 2021 -$6.66 M -$10.7 M -$877 K -8.95% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$5.78 M -$11.8 M -$1.14 M -10.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$4.64 M -$11.6 M +$1.36 M +10.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$6 M $27.3 M +$38.4 M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$44.4 M -$9.8 M +$1.21 M +11% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-10
Q2 2020 -$45.6 M -$10.6 M +$2.37 M +18.2% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-10
Q1 2020 -$48 M -$12.9 M -$1.29 M -11.1% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-10
Q4 2019 -$46.7 M -$11 M -$538 K -5.12% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$46.1 M -$11 M -$506 K -4.82% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-25
Q2 2019 -$45.6 M -$13 M -$1.35 M -11.6% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-25
Q1 2019 -$44.3 M -$11.6 M +$2.66 M +18.6% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-25
Q4 2018 -$46.9 M -$10.5 M +$1.42 M +11.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$48.4 M -$10.5 M +$2.22 M +17.4% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-09
Q2 2018 -$50.6 M -$11.6 M +$3.35 M +22.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-09
Q1 2018 -$53.9 M -$14.3 M +$1.74 M +10.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-09
Q4 2017 -$55.7 M -$11.9 M -$843 K -7.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$54.8 M -$12.7 M -$2.42 M -23.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$52.4 M -$15 M -$6.34 M -73.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$46.1 M -$16 M -$9.69 M -153% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$36.4 M -$11.1 M -$5.05 M -83.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$31.3 M -$10.3 M -$7.15 M -227% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$24.2 M -$8.65 M +$11.6 M +57.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$35.8 M -$6.35 M -$4.43 M -232% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$31.3 M -$6.04 M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 -$3.15 M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 -$20.2 M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 -$1.91 M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.